Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 12/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 12/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 12/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 12/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 12/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 12/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3277400 | 1.00 | PSEN1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3277124 | 1.00 | PSEN1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3276435 | 0.88 | PSEN1 (0.36) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3277401 | 0.88 | PSEN1 (0.35) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3278486 | 0.87 | PSEN1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3277065 | 0.87 | PSEN1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3277044 | 0.86 | PSEN1 (0.42) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3276270 | 0.81 | ESR1 (0.44) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5213734 | 0.81 | PSEN1 (0.44) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4953709 | 0.80 | ESR1 (0.52) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7696221-B2 | Thienoisoquinoline-phenylsulfonamides and their use as ER-NFκB inhibitors | WYETH LLC (US) | 2010-04-13 | — | — | US | claimed |
| US-20060154875-A1 | Thienoisoquinoline-phenylsulfonamides and their use as ER-NFkappaB inhibitors | WYETH (US) | 2006-07-13 | — | — | US | claimed |
| US-7696221-B2 | Thienoisoquinoline-phenylsulfonamides and their use as ER-NFκB inhibitors | WYETH LLC (US) | 2010-04-13 | — | — | US | disclosed |
| US-20060154875-A1 | Thienoisoquinoline-phenylsulfonamides and their use as ER-NFkappaB inhibitors | WYETH (US) | 2006-07-13 | — | — | US | disclosed |
| WO-2006069182-A2 | THIENOISOQUINOLINE-PHENYLSULFONAMIDES AND THEIR USE AS ER-NFkB INHIBITORS | WYETH (US) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154875-A1 | Thienoisoquinoline-phenylsulfonamides and their use as ER-NFkappaB inhibitors | NFKBIA, IKBKB, IKBKE | PSEN1 1085/4885PSEN2 1210/4885APH1B 3762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.